share_log

亿胜生物科技(01061.HK):批准于中国大陆商业化不含防腐剂单剂量玻璃酸钠滴眼液(0.1%)

ESSEX BIO-TECH (01061.HK): Approved for commercialization in mainland China of preservative-free single-dose sodium hyaluronate eye drops (0.1%).

Gelonghui Finance ·  Dec 24, 2024 05:21

On December 24, Glorify Holdings announced that ESSEX BIO-TECH (01061.HK) has received approval from the National Medical Products Administration to register and commercialize preservative-free single-dose Sodium Hyaluronate eye drops (0.1%) in mainland China.

The approved product is a preservative-free single-dose eye drop containing 0.1% (0.4ml:0.4mg) Sodium Hyaluronate, suitable for treating and relieving various endogenous eye diseases (such as Sjögren's syndrome, Stevens-Johnson syndrome, dry eye), exogenous eye diseases, and injuries caused by surgery, medications, trauma, and/or wearing contact lenses. The group's other preservative-free single-dose eye drop products include Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops (0.3%), Beifuzi (rb-bFGF) eye drops, Moxifloxacin hydrochloride eye drops, and Dextran Sodium eye drops.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment